Although phage therapy offers a promising complement to existing antimicrobials, routine clinical implementation requires harmonized regulatory pathways, scalable production standards, and rigorously designed clinical trials. Strategic international collaboration and integration of emerging technologies will be pivotal in advancing phage therapy toward sustainable clinical adoption.
Bhale et al. (Fri,) studied this question.